Iovance Biotherapeutics, Inc.
News
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Position Lowered by Candriam S.C.A.
Zolmax Candriam S.C.A. lowered its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 52.8% in the 2nd quarter, according to its most recent disclosure with the Securities...\n more…
IOVA Makes Notable Cross Below Critical Moving Average
Market News Video In trading on Friday, shares of Iovance Biotherapeutics Inc (IOVA) crossed below their 200 day moving average of 10.11, changing hands as low as 10.05 per share. Iovance Biotherapeutics...\n more…
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Fool.com Headlines Iovance Biotherapeutics (NASDAQ: IOVA) investors received great news earlier this year when the U.S. Food and Drug Administration granted it accelerated approval for the company's cell therapy...\n more…
Iovance Biotherapeutics to Present at Upcoming Conferences
Globe Newswire SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the Company ), a biotechnology company focused on innovating, developing, and...\n more…
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Benzinga Iovance Biotherapeutics's IOVA short percent of float has fallen 3.22% since its last report. The company recently reported that it has 59.33 million shares sold short, which is 21.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.62 days to cover their short positions on average.\n more…
3 Monster Biotech Stocks to Buy Before 2025
Fool.com Headlines Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs...\n more…